/Dexcom%20Inc%20logo%20on%20sign-by%20Michael%20Vi%20via%20Shutterstock.jpg)
Based in San Diego, California, DexCom, Inc. (DXCM), with a market cap of $44.8 billion, is a leader in the medical device sector, specializing in continuous glucose monitoring systems for diabetes management. The company is set to unveil its fiscal Q2 earnings results after the market closes on Thursday, Jul. 25.
Ahead of this event, analysts expect DXCM to report a profit of $0.39 per share, up 14.7% from $0.34 per share in the year-ago quarter. The company holds a solid track record of surpassing Wall Street's bottom-line estimates in each of the past four quarters. In the most recent quarter, the company’s adjusted EPS of $0.32 climbed a notable 88.2% annually, surpassing the consensus estimate by a solid 18.5% margin due to strong demand for glucose monitoring.